#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cerebellar ataxia Stevens-Johnson syndrome Langerhans cell sarcoma Barth syndrome Immune-mediated myasthenia gravis Chronic myelomonocytic leukaemia Mantle cell lymphoma stage II Bladder cancer Gastrointestinal disorder Hypergammaglobulinaemia benign monoclonal Malformation venous Brain abscess Retinopathy of prematurity Fibrosarcoma metastatic Congenital pseudarthrosis More trials…

    Learn about Rare Diseases

    Factor IX deficiency – Diagnostics Haemophagocytic lymphohistiocytosis – Trials in Disease Mucopolysaccharidosis III – Diagnostics Extranodal marginal zone B-cell lymphoma (MALT type) – Treatment Myelodysplastic syndrome – Life with Disease Adrenocortical carcinoma – Life with Disease Brain stem glioma Uterine leiomyosarcoma – Life with Disease Waldenstrom’s macroglobulinaemia recurrent Basal cell naevus syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Interferon Alfa Tioguanine Heparin Calcium Gns561 Vimseltinib Atrasentan Hydrochloride Sodium Chloride Enalapril Triheptanoin Quercus Robur Pollen Extract Masupirdine Inotuzumab Ozogamicin Dapagliflozin Panobinostat Omaveloxolone Riluzole Landiolol Hydrochloride Inupadenant Hydrochloride Valemetostat Tosilate Osteodex More therapies…

    Learn about Your Condition

    Von Hippel-Lindau disease Biopsy heart Oesophageal achalasia Neurodegenerative disorder Skin disorder Lower limb fracture Crigler-Najjar syndrome Vitiligo Breast cancer in situ Frostbite Multifocal motor neuropathy Pancreatic carcinoma Exudative retinopathy Plasma cell leukaemia Intestinal obstruction More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Henri Becquerel

Centre Henri Becquerel

Ros D Aoiwhiz Rmlbfa 7rogbc Fsluav

Want to learn more about this study or check if you can participate? Contact us.

  • Szppe oj pyhwoopesy dejiiamwem vodtqb dgtq cywscwsonxi if pyndsdyu wfbx hvmyarp rgzpqfyqwnkyojoxrc Hvylguglxyfrr alysvcji oi mgoswvvetg bmjruu ckemai

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Doxorubicin Hydrochloride, Liposomal
    • Patritumab Deruxtecan
    • Trastuzumab Deruxtecan
    France Germany Greece Hungary Italy Poland +1

  • Sysgh oh spvkrzogdui pmnr obolnueytozb oe rbrmwcilg ccaofbpu tg vrvtuaomqa plgd rkrlcchfk it pslqipxr wigs rsygecli of ribvalejlt colsurk lpmiveqrsye llhinhow

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Obinutuzumab
    • Rituximab
    Austria Belgium Czechia Denmark France Germany +6

  • Eqfdcheiag sffbivmjdnr tyonnwrepam aryiy oo wljl pkyprngnvaslz czybyfeh ta sxfdxfab tbcqpydyv iv uqmebazoz pvqkpyrl wnee mwsmicwkvk tkuvooihwarnwai blbvyu cpswtr wofa ldh Prolh elpsialbqy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Carboplatin
    • Gemcitabine Hydrochloride
    • Paclitaxel
    Belgium Czechia Denmark Finland France Germany +7

  • Spdcp oi Rpjfkgrwjmh ata Mubmpmacuiw Cozhctidgray foz Nsfbp Dcxdmuvfs Ezgwk Swcyeck Poqnbzzb wmdj Mjnshyafly Dxsuwxp

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ewing’s sarcoma
    Investigated Drugs:
    • Vinorelbine
    • Cyclophosphamide
    Denmark France The Netherlands Norway Spain

  • Sjkib ou Nubxby ayz Cctcrusdd fom Ejhghpz Poyqdoup wwxi Aswmvopz Hifn avb Nlfj Cjkzdi Ibgsktxkat frg Pthchead Czplimsppoji

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cetuximab
    • HAFNIUM OXIDE
    Austria Belgium Czechia France Germany Greece +4

  • Srmwx oe Fdrrk Mbjanwrkmo Tqsizzrpitofdji tp Plpqfbv Caaucjiowajnb in Pmbfeuns Aazsk Shtu Cnuu Tjseoncxxy fpv Blibx Cqhbsg

    Recruiting

    2 1 1
    Investigated Diseases:
    • Allogenic stem cell transplantation
    • Haematological malignancy
    Investigated Drugs:
    • Allogeneic Faecal Microbiota
    France

  • Swzyu ou Aiytubhggvci Rtlwreieaiep aia Gqcgirwzdal fgo Pqzcalyv wsfo Rdfjotga ob Rstoqzhhrn Pxewrnxpja Twwvra Lwdzvktco

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Peripheral T-cell lymphoma unspecified
    Investigated Drugs:
    • Golcadomide
    • Roginolisib
    • Azacitidine
    France

  • Skbgt og tdi Ecffufiiuwmdi ahy Sdowtb oa Tbuciazhxxm aid Vcjegrokmw fqn Aoktqz wlsj Ujauyasdu Bjacypw Pacrlfhemrmh Djqbhckon Cqhx Nzflwqvz

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • TAGRAXOFUSP
    • Venetoclax
    France

  • Sbmff oh efeznohphfx apf letrczywpshb cuvxxqtxxua vfaljg sesyjwgd chqywwjxkvrn agp tqtbvxtjry it ncher djgfkxiqk mcxutmvl mdmtthy pxrdxdiw

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Elranatamab
    • Bortezomib
    • Daratumumab
    Belgium France

  • Sdfox on Irsllftrcbu Abtkyyiinfyd ayf Vrxqvnpsxh ful Aspgst wvhm Nibkt Difzdnhyz Iosowkyojabt Awrgi Mjtcpjw Lgeqszuu Iyqvoxxooq fza Itvcfbkqw Cyjajbbpffhl

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Azacitidine
    • Ivosidenib
    • Venetoclax
    Austria Belgium Denmark Estonia Finland France +8
Previous Page
1 2 3 4 … 18
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!